StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
RAAJMEDI.BO$79.43-5.00%
Fair $79.43+0.0%

RAAJMEDI.BO

Raaj Medisafe India Limited

Consumer Cyclical / Packaging & ContainersBSE

$79.43

-4.18 (-5.00%)

Fairly Valued+0.0%Fair Value $79.43Fund rank 20/100 · Data gapFallback financials|
SA 38/D
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 14%

FCF escenarios

weak_data · normalized FCF $-73.6M · quality 28.0/100

Data gap 20/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 6/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

38/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · RAAJMEDI.BOLocal privado en este navegador · Raaj Medisafe India Limited
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.0B

P/E

13.0x

↓

EV/EBITDA

16.0x

↑

ROE

22.8%

↑

Gross Margin

23.4%

↓

Debt/Equity

1.28

↑
52-Week Range$79
$64$102

TradingView lightweight chart

RAAJMEDI.BO price, volumen y niveles de valoración

Último $79.43Periodo +1554.8%
Fair value: $79.43

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+21.6%

FCF CAGR

—

FCF margin

-23.7%

FCF / Net income

-2.41x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $624.2M · net income $61.3M · FCF $-148.0M

2022-FY → 2025-FY

Gross margin

23.4%-3.7% pts

Operating margin

11.3%-1.2% pts

Net margin

9.8%+1.1% pts

FCF margin

-23.7%-27.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$624.2M$624.2M$432.5M$386.2M$346.9M
Net Income$61.3M$61.3M$33.3M$33.3M$30.1M
EBITDA$87.2M$87.2M$65.8M$55.8M$51.1M
EPS4.604.603.073.062.82
Gross Margin23.4%23.4%26.9%25.0%27.1%
Operating Margin11.3%11.3%13.4%12.6%12.6%
Net Margin9.8%9.8%7.7%8.6%8.7%
Balance Sheet
Debt/Equity1.281.282.392.083.14
Cash Flow
Free Cash Flow$-148.0M$-148.0M$-73.6M$-15.5M$12.3M
Returns
ROE22.8%22.8%30.7%44.5%72.6%
Valuation
P/E13.0013.0016.617.9814.02
EV/EBITDA15.9615.9612.387.5510.80
P/B3.893.895.133.5510.18
Growth & Yield
Revenue Growth44.3%44.3%12.0%11.3%—
EPS Growth49.8%49.8%0.3%8.5%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

15.3%

exigente

EPS terminal req.

$7.05

Spread vs growth

34.6%

5Y implied EPS CAGR

13.1%

razonable

EPS terminal req.

$8.53

Spread vs growth

36.7%

10Y implied EPS CAGR

11.6%

razonable

EPS terminal req.

$13.73

Spread vs growth

38.3%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -15.9%

Total return

-15.9%

Start / end P/E

30.8x → 17.3x

EPS bridge

3.07 → 4.60

Residual

-21.9%

EPS growth+49.8%
Multiple rerating-43.9%
Dividend+0.0%
Residual / FX / buybacks / cross-term-21.9%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.